HDFC Pharma and Healthcare Fund (Regular)
HDFC Mutual Fund · benchmark Nifty 500 TRI · 3.1 years old · AMFI code 152084
A+ (top 10% of its peer group), score 80.2 out of 100. Describes the past, not a forecast.
Returns against the index
| Period | Fund | Index (TRI) | Difference | Rank in category |
|---|---|---|---|---|
| 6 months | 16.9% | 2.5% | +14.4% | 5 / 17 |
| 1 year | 24.8% | -1.0% | +25.8% | 1 / 16 |
| 3 years (a year) | 29.8% | 12.0% | +17.8% | 1 / 11 |
| 5 years (a year) | – | – | – | – |
Growth option, point to point to 5 Nov 2026; periods over a year are annualised (CAGR). Index returns use the total-return index, which includes dividends.
Risk
Portfolio
Top 10 holdings, September 2026 portfolio.
Common questions
What is the NAV of HDFC Pharma and Healthcare Fund (Regular plan)?
₹21.80 on 5 Nov 2026 (Growth option).
What is the expense ratio of HDFC Pharma and Healthcare Fund (Regular)?
2.12% a year; the Direct plan's is 1.04%.
What return has HDFC Pharma and Healthcare Fund given over 3 years?
29.8% a year (Regular plan) over the 3 years to 5 Nov 2026, against 12.0% for the Nifty 500 total-return index.
What does HDFC Pharma and Healthcare Fund invest in?
Its largest holdings are Divis Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., with 38 stocks in all (September 2026 portfolio).
How is HDFC Pharma and Healthcare Fund rated?
A+: 2 of 11 Regular plans in Thematic: Pharma & Healthcare, on its track record. This describes the past and is not a recommendation.
Data as of 5 Nov 2026: NAVs from AMFI, index data from NSE Indices, portfolios from HDFC Mutual Fund's monthly disclosure. Updated every weekday. Read the scheme documents before investing.